Tronox Holdings plc announced its third quarter 2026 earnings release will be published on November 4 after market close. A webcast conference call to discuss the results will follow on November 5 at 9:00 AM ET, open to the public online. Investors can register and access slides via the company's website. Tronox is a leading global producer of titanium products, and this earnings update will provide insights into its recent performance and outlook.
Tronox's upcoming third quarter 2026 earnings release is set for November 4, with a webcast conference call on November 5. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: Of 38 priced US stocks, 20 rose and 18 fell. Ecolab Inc. (ECL) traded at USD 277.16 with a 1-day gain of 1.26% and a typical hold time of 90 days, while Newmont Corporation (NEM) was priced at USD 116.06, up 1.21%, with a shorter hold time of 58 days. In contrast, Standard Lithium Ltd (SLI) declined 1.15% to USD 1.72 and had the shortest hold time of 22 days on Pluang.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
